J Korean Med Sci.  2009 Jun;24(3):488-492. 10.3346/jkms.2009.24.3.488.

Stereotactic Body Radiotherapy for Isolated Para-aortic Lymph Node Recurrence after Curative Resection in Gastric Cancer

• Kim MS
• Yoo SY
• Cho CK
• Yoo HJ
• Yang KM
• Kang JK
• Lee DH
• Lee JI
• Bang HY
• Kim MS
• Kang HJ

• KMID: 1779168
• DOI: http://doi.org/10.3346/jkms.2009.24.3.488

Abstract

The aim of this study was to investigate whether stereotactic body radiotherapy (SBRT) can salvage gastric cancer patients with para-aortic lymph node (PALN) recurrence. From January 2003 to December 2006, 7 patients were treated for isolated PALN recurrence from gastric cancer after curative resection. Follow up durations ranged from 19 to 33 months (median; 26 months), and SBRT doses from 45 Gy to 51 Gy (median 48 Gy) in 3 fractions. Disease progression-free and overall survivals and toxicities were recorded. Response to treatment was assessed by computed tomography. Final patient outcomes were as follows: 2 were alive without evidence of disease, 3 remained alive with disease, and 2 patients died of disease. Five of 7 patients showed complete response and 2 patients partial response between 3 and 11 months after SBRT. Three-year overall and disease progression-free survival rates post-SBRT were 43% and 29%, respectively. No severe complication was detected during follow-up. Selected patients with isolated PALN recurrence can be salvaged by SBRT without severe complications.

Keyword

Stomach Neoplasms; Recurrence; Radiotherapy

MeSH Terms

Adult
Aged
Disease-Free Survival
Female
Humans
Lymph Nodes/surgery
Lymphatic Metastasis
Male
Middle Aged
Neoplasm Recurrence, Local/*radiotherapy/surgery
Radiosurgery
Radiotherapy Dosage
Recurrence
Stomach Neoplasms/diagnosis/pathology/*surgery
Survival Analysis

Figure

• 

  Fig. 1 Planning of 48 Gy SBRT. Gross tumor volume (GTV) was defined as the volume (mL) of the visible LN (innermost line). Radiation dose was prescribed to the 80% isodose line of the maximum dose covering the GTV plus a 2 mm margin. The outermost line is the 30% isodose line.

• 

  Fig. 2 Three-year overall survival (OS) and disease progression-free survival rates (DPFS) were 43% and 29%, respectively.

Reference

1. Park JG, editor. Cancer Incidence of Korea 1999-2001. 2005. Seoul, Republic of Korea: Ministry of Health and Welfare.

2. Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare. Vital Statistics of Japan 2002. 2004. Tokyo: Health and Welfare Statistics Association;290.

3. Saito H, Fukumoto Y, Osaki T, Fukuda K, Tatebe S, Tsujitani S, Ikeguchi M. Prognostic significance of level and number of lymph node metastases in patients with gastric cancer. Ann Surg Oncol. 2007. 14:1688–1693.

4. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, Meyer S, Plukker JT, Van Elk P, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H. Dutch Gastric Cancer Group. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999. 340:908–914.

5. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P. Surgical co-operative group. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer. 1999. 79:1522–1530.

6. Nashimoto A, Sasaki J, Sano M, Tanaka O, Tsutsui M, Tsuchiya Y, Makino H. Disease-free survival for 6 years and 4 months after dissection of recurrent abdominal paraaortic nodes (no. 16) in gastric cancer: report of a case. Surg Today. 1997. 27:169–173.

7. Takahashi S. Study of para-aortic lymph node metastasis of gastric cancer subjected to superextensive lymph node dissection. Nippon Geka Gakkai Zasshi. 1990. 91:29–35.

8. Yonemura Y, Miyazaki I. Surgical techniques and clinical significance of radical lymphadenectomy for paraaortic lymph nodes in advanced gastric cancer. J Clin Surg. 1989. 777–784.

9. Kitamura M, Arai K, Iwasaki Y. Clinicopathological studies on paraaortic lymph node metastasis and postoperative quality of life in gastric cancer patients. Jpn J Gastroenterol Surg. 1994. 2073–2078.

10. Imamura H, Matsuyama Y, Shimada R, Kubota M, Nakayama A, Kobayashi A, Kitamura H, Ikegami T, Miyagawa SI, Kawasaki S. A study of factors influencing prognosis after resection of hepatic metastases from colorectal and gastric carcinoma. Am J Gastroenterol. 2001. 96:3178–3184.

11. Taniguchi H, Takahashi T, Sawai K, Yamaguchi T, Hagiwara A, Kitamura K, Hoshima M, Masuyama M, Mugitani T, Takada A, Yamaguchi A. Comparison in survival between hepatic metastases of gastric and colorectal cancers. Hepatogastroenterology. 1997. 44:897–900.

12. Sakamoto Y, Ohyama S, Yamamoto J, Yamada K, Seki M, Ohta K, Kokudo N, Yamaguchi T, Muto T, Makuuchi M. Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery. 2003. 133:507–511.

13. Koga R, Yamamoto J, Ohyama S, Saiura A, Seki M, Seto Y, Yamaguchi T. Liver resection for metastatic gastric cancer: experience with 42 patients including eight long-term survivors. Jpn J Clin Oncol. 2007. 37:836–842.

14. Schwarz RE, Zagala-Nevarez K. Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy. Ann Surg Oncol. 2002. 9:394–400.

15. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000. 87:236–242.

16. Park CH, Byun JY, Kim BK, Kim IC. Recurrent gastic cancer after curative surgery. J Korean Cancer Assoc. 1998. 30:488–496.

17. Lee HJ, Cho SJ, Yang HK, Lee KU, Choe KJ, Kim JP. Retrospective analysis of treatment results of recurrent gastric cancer. J Korean Cancer Assoc. 2000. 506–515.

18. Park SM, Lee CH, Park CH, Kim W, Ahn CJ, Lim GW, Park WB, Kim SN, Kim IC. Reoperation of recurrent gastric cancer. Cancer Res Treat. 2001. 33:478–482.

19. Ha TK, Kwon SJ. Clinicopathological characteristics for type of recurrence in gastric cancer patients. J Korean Gastric Cancer Assoc. 2007. 7:23–30.

20. Minami K, Tsutani Y, Suzuki T, Miyahara E, Kameda A, Noso Y. Chemotherapy for patients with non-curative advanced or recurrent gastric cancer in our hospital. Gan To Kagaku Ryoho. 2008. 35:55–60.

21. Murakami M, Morikawa A, Okabe R, Hayashi K, Miyazawa K, Iijima S, Ozaki K, Suzuki A, Koyama Y, Sugiyama A. Three cases of recurrent gastric cancer responding to TS-1 therapy following combination therapy with 5-fluorouracil, mitomycin C and cisplatin. Gan To Kagaku Ryoho. 2002. 29:767–770.

22. Teraishi F, Suzuki T, Nakamoto M, Chikuba A, Nezu M, Shimamura H, Takiue T, Chikuba H. Marked response to S-1 chemotherapy for para-aortic lymph node metastasis arising from gastric cancer. Gan To Kagaku Ryoho. 2007. 34:1857–1859.